Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Effect of Proton-Pump Inhibitors on Glucose and Insulin Metabolism on Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author(s): Adriana Sánchez-García, Mario Simental-Mendía and Luis E. Simental-Mendía*

Volume 26, Issue 32, 2020

Page: [4007 - 4013] Pages: 7

DOI: 10.2174/1381612826666200523170718

Price: $65

Abstract

Background: Some studies have revealed an improvement in glucose metabolism after proton-pump inhibitors (PPI) therapy; however, this evidence is inconclusive and limited.

Objective: The study aimed to examine the effect of PPI on glucose and insulin metabolism in patients with type 2 diabetes through a systematic review and meta-analysis.

Methods: Only randomized controlled trials evaluating the impact of PPI on glucose or insulin concentrations in type 2 diabetes were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases. A meta-analysis was conducted using a random-effects model and generic inverse variance method. Sensitivity analysis was performed using the leave-one-out method.

Results: Meta-analysis revealed no significant effect of PPI intervention on fasting glucose (mean difference [MD] -11.42 [95% CI, -29.68 to 6.83], I2 = 80%, p = 0.22), fasting insulin (MD 1.51 [95% CI, -0.36 to 3.37], I2 = 32%, p = 0.11), HOMA-IR (MD -0.16 [-0.98 to 0.65], I2 = 0%, p = 0.70), HOMA-β (MD 19.97 [-21.59 to 61.52], I2 = 71%, p = 0.35), and HbA1c concentrations (MD -0.34 [-0.99 to 0.31], I2 = 89%, p = 0.30).

Conclusion: The treatment with PPI, in the short term, had no significant effects on glucose and insulin metabolism in patients with type 2 diabetes.

Keywords: Proton-pump inhibitors, glucose, insulin, type 2 diabetes, therapy, generic.

« Previous Next »
[1]
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver 2017; 11(1): 27-37.
[http://dx.doi.org/10.5009/gnl15502] [PMID: 27840364]
[2]
Mössner J. The indications, applications and risks of proton pump inhibitors. Dtsch Arztebl Int 2016; 113(27-28): 477-83.
[http://dx.doi.org/10.3238/arztebl.2016.0477] [PMID: 27476707]
[3]
Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther 2017; 34(5): 1070-86.
[http://dx.doi.org/10.1007/s12325-017-0532-9] [PMID: 28429247]
[4]
Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017; 80(5): 925-37.
[http://dx.doi.org/10.1007/s00280-017-3426-2] [PMID: 28861639]
[5]
Boj-Carceller D. Proton pump inhibitors: impact on glucose metabolism. Endocrine 2013; 43(1): 22-32.
[http://dx.doi.org/10.1007/s12020-012-9755-3] [PMID: 22886351]
[6]
Hao S, Sun J, Tian X, Sun X, Zhang Z, Gao Y. Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects. J Pharm Pharmacol 2014; 66(8): 1133-9.
[http://dx.doi.org/10.1111/jphp.12237] [PMID: 24628303]
[7]
Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 2009; 52(8): 1680-2.
[http://dx.doi.org/10.1007/s00125-009-1390-z] [PMID: 19455306]
[8]
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011; 2(12): 217-20.
[http://dx.doi.org/10.4239/wjd.v2.i12.217] [PMID: 22174957]
[9]
Crouch MA, Mefford IN, Wade EU. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med 2012; 25(1): 50-4.
[http://dx.doi.org/10.3122/jabfm.2012.01.100161] [PMID: 22218624]
[10]
Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2014; 2(9): 710-8.
[http://dx.doi.org/10.1016/S2213-8587(14)70115-9] [PMID: 24997559]
[11]
Takebayashi K, Sakurai S, Suzuki T, et al. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocr J 2014; 61(10): 1031-9.
[http://dx.doi.org/10.1507/endocrj.EJ14-0208] [PMID: 25185672]
[12]
González-Ortiz M, Martínez-Abundis E, Mercado-Sesma AR, Álvarez-Carrillo R. Effect of pantoprazole on insulin secretion in drug-naïve patient with type 2 diabetes. Diabetes Reserach and Clinical Practice 2015; e11-113..
[http://dx.doi.org/10.1016/j.diabres.2015.01.039]
[13]
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[14]
Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions Version 502. London: The Cochrane Collaboration 2009.
[15]
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
[http://dx.doi.org/10.1186/1471-2288-5-13] [PMID: 15840177]
[16]
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
[http://dx.doi.org/10.1186/1471-2288-14-135] [PMID: 25524443]
[17]
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28(5): 633-42.
[http://dx.doi.org/10.1002/ptr.5045] [PMID: 23922235]
[18]
Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia 2013; 56(1): 22-30.
[http://dx.doi.org/10.1007/s00125-012-2714-y] [PMID: 23011351]
[19]
Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2012; 97(11): E2105-8.
[http://dx.doi.org/10.1210/jc.2012-1720] [PMID: 22904177]
[20]
Gómez-Izquierdo JC, Yu OHY. The influence of proton-pump inhibitors on glycemic control: A systematic review of the literature and a meta-analysis. Can J Diabetes 2017; 41(4): 351-61.
[http://dx.doi.org/10.1016/j.jcjd.2016.11.004] [PMID: 28373033]
[21]
Hove KD, Færch K, Bödvarsdóttir TB, Karlsen AE, Petersen JS, Vaag A. Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis. Diabetes Res Clin Pract 2010; 90(3): e72-4.
[http://dx.doi.org/10.1016/j.diabres.2010.09.007] [PMID: 20888658]
[22]
Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002; 51(3): 686-90.
[http://dx.doi.org/10.2337/diabetes.51.3.686] [PMID: 11872667]
[23]
Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet beta-cells from pancreatic duct cells and an increase in functional beta-cell mass. J Clin Endocrinol Metab 2005; 90(6): 3401-9.
[http://dx.doi.org/10.1210/jc.2004-0761] [PMID: 15769977]
[24]
Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6(6): 789-92.
[http://dx.doi.org/10.3748/wjg.v6.i6.789] [PMID: 11819697]
[25]
Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010; 123(3)(Suppl.): S28-37.
[http://dx.doi.org/10.1016/j.amjmed.2009.12.007] [PMID: 20206729]
[26]
Bödvarsdóttir TB, Hove KD, Gotfredsen CF, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 2010; 53(10): 2220-3.
[http://dx.doi.org/10.1007/s00125-010-1825-6] [PMID: 20585936]
[27]
Lin HC, Hsiao YT, Lin HL, et al. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study. Medicine (Baltimore) 2016; 95(28)e4195
[http://dx.doi.org/10.1097/MD.0000000000004195] [PMID: 27428221]
[28]
Barchetta I, Guglielmi C, Bertoccini L, et al. IMDIAB group. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetol 2015; 52(5): 873-80.
[http://dx.doi.org/10.1007/s00592-015-0721-4] [PMID: 25716766]
[29]
Takebayashi K, Inukai T. Effect of proton pump inhibitors on glycemic control in patients with diabetes. World J Diabetes 2015; 6(10): 1122-31..
[http://dx.doi.org/10.4239/wjd.v6.i10.1122] [PMID: 26322158]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy